Knight Therapeutics | GUD - Gross Profit On Sales


Knight Therapeutics reported CAD64.72M in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
Acasti Pharma USD 75K 30K Mar/2021
Akebia Therapeutics USD 47.28M 1.7M Dec/2025
Alaunos Therapeutics USD -1.13M 1.11M Sep/2024
Aurora Cannabis CAD 29.79M 16.83M Mar/2026
Avita Medical AUD 14.31M 639K Dec/2025
Canopy Growth CAD 8.26M 13.2M Mar/2026
Cronos Group USD 28.45M 9.3M Jun/2026
Dianthus Therapeutics USD 463K 179K Mar/2026
Ionis Pharmaceuticals USD 265M 22M Jun/2026
IQVIA Holdings USD 1.44B 368M Jun/2026
Knight Therapeutics CAD 64.72M 8.91M Dec/2025
Moderna USD -566M 792M Mar/2026
Omeros USD -33.16M 18.52M Jun/2024
Organigram Holdings CAD 16.41M 6.91M Mar/2026
Organon & Co USD 847M 64M Jun/2026
Revvity USD 416.87M 29.21M Jun/2026
Tectonic Therapeutic USD 0 0 Mar/2025
Tilray USD 57.47M 10.16M Jun/2025
Viatris USD 1.57B 193.9M Jun/2026
Xeris Pharmaceuticals USD 72.55M 404K Mar/2026